Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Osmolex ER
- Development stage
- Unknown
- Lead developer
- Osmotica Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Osmolex ER is an extended-release oral tablet formulation of amantadine hydrochloride, developed by Adamas Pharmaceuticals (acquired by Supernus Pharmaceuticals). It is FDA-approved for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adult patients. The drug utilizes a specialized osmotic pump delivery system (Osmodex) consisting of an immediate-release outer layer and an extended-release core, which provides a consistent release profile throughout the day. While the exact mechanism of amantadine in treating Parkinson's disease is not fully elucidated, it is known to act as a weak non-competitive NMDA receptor antagonist, facilitate the release of dopamine, and inhibit dopamine reuptake, thereby helping to control motor symptoms such as stiffness, tremors, and dyskinesia.
- Brand names
- Osmolex ER
- Other names
- Osmolex CRamantadine hydrochloride extended-release
02
Targets
DAT (Dopamine plasma membrane transport protein)NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on Osmolex ER.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Osmolex ER.